# CHRM4 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The CHRM4 gene encodes the M4 muscarinic acetylcholine receptor, a G protein-coupled receptor predominantly expressed in the central nervous system, particularly the striatum, hippocampus, and cortex. Its canonical signaling involves Gi/o protein coupling, leading to inhibition of adenylyl cyclase and modulation of ion channels.
- M4 plays a critical role in modulating dopaminergic, glutamatergic, and GABAergic neurotransmission, functioning as both an autoreceptor and a heteroreceptor. This makes it a significant target for conditions like schizophrenia, Alzheimer's disease, Parkinson's disease, and chronic pain.
- Structural biology has elucidated the active-state conformation of M4 bound to Gi proteins (PDB: 6KP9), revealing key residues like Asp105 and Trp400 involved in ligand binding and receptor activation, facilitating structure-based drug design.
- Pathogenic germline mutations in CHRM4 are associated with neurodevelopmental disorders such as intellectual disability and autism spectrum disorder, while somatic mutations are implicated in various cancers, including glioblastoma and colorectal cancer, where they can confer gain-of-function or loss-of-function phenotypes.
- M4 is a high-priority therapeutic target, with selective positive allosteric modulators (PAMs) like LY2033298 and VU0467154 under investigation for schizophrenia and Alzheimer's disease, aiming to leverage its role in cholinergic and dopaminergic signaling pathways.

---

## Executive Summary & Key Metadata

The cholinergic receptor muscarinic 4 (CHRM4) gene encodes the M4 muscarinic acetylcholine receptor, a G protein-coupled receptor (GPCR) of the class A rhodopsin-like family. M4 is predominantly expressed in the central nervous system (CNS), particularly in the striatum, hippocampus, and cortex, where it functions as a critical autoreceptor and heteroreceptor modulating dopaminergic, glutamatergic, and GABAergic neurotransmission. Its canonical signaling proceeds through the Gi/o family of heterotrimeric G proteins, leading to inhibition of adenylyl cyclase, modulation of ion channels, and activation of downstream kinase cascades. Beyond its well-established role in motor control, cognition, and analgesia, CHRM4 has emerged as a high-priority drug target for schizophrenia, Alzheimer’s disease, Parkinson’s disease, and chronic pain. Recent structural biology efforts have resolved the active-state conformation of M4 bound to selective agonists and G proteins, enabling structure-based drug design. Additionally, accumulating evidence implicates CHRM4 dysregulation in various malignancies, including glioblastoma, colorectal cancer, and hepatocellular carcinoma, where it modulates proliferative and migratory signaling. This reference manual provides an exhaustive analysis of the CHRM4 gene, from its genomic architecture and transcriptional regulation to its three-dimensional protein structure, signaling networks, pathogenic mutations, pharmacogenomic relevance, and bioinformatic resources.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | CHRM4 |
| **UniProt Accession** | P08173 |
| **Representative PDB ID** | 6KP9 (active-state M4–Gi complex) |
| **Chromosomal Locus** | 11q12.2 (GRCh38: chr11:46,381,345–46,385,202; minus strand) |
| **Primary Molecular Function** | G protein-coupled receptor; Gi/o-mediated signaling; acetylcholine binding |
| **Disease & Pathology Associations** | Schizophrenia (therapeutic target), Alzheimer’s disease, Parkinson’s disease, drug addiction, chronic pain, glioblastoma, colorectal cancer, hepatocellular carcinoma |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The CHRM4 gene is located on the long arm of chromosome 11 at cytogenetic band 11q12.2. In the GRCh38 assembly, the gene spans approximately 3.86 kilobases (kb) of genomic DNA, from position 46,381,345 to 46,385,202 on the minus (reverse) strand. The gene comprises a single coding exon, a feature shared with most muscarinic receptor genes, which lack introns in their coding regions. This intronless architecture has significant implications for transcriptional regulation and mutation susceptibility, as any genomic variant within the coding region directly affects the mature mRNA without the possibility of alternative splicing to bypass deleterious mutations.

The immediate genomic neighborhood of CHRM4 includes several genes with which it may share regulatory elements. The gene is flanked by *TSPAN18* (tetraspanin 18) on the telomeric side and *OR4A47* (olfactory receptor 4A47) on the centromeric side. Notably, *TSPAN18* has been implicated in neuropsychiatric disorders, and the proximity of these genes raises the possibility of shared enhancer elements or long-range chromatin interactions that could coordinately regulate their expression in neuronal tissues.

### 1.2 Promoter Architecture and Transcription Factor Binding

The promoter region of CHRM4 lacks a canonical TATA box, a characteristic common to many GPCR genes. Instead, the promoter is GC-rich and contains multiple Sp1 (specificity protein 1) binding sites, which are essential for basal transcriptional activity. Electrophoretic mobility shift assays and chromatin immunoprecipitation studies have demonstrated that Sp1 binds to a region approximately −100 to −50 base pairs upstream of the transcription start site (TSS), and mutation of these Sp1 motifs reduces promoter activity by 60–70% in neuronal cell lines.

Additional transcription factor binding sites have been identified through in silico analysis and experimental validation. These include:

- **CREB (cAMP response element-binding protein)**: A cAMP response element (CRE) is located at position −350 to −343. Activation of the cAMP/PKA pathway leads to CREB phosphorylation and subsequent upregulation of CHRM4 transcription, providing a positive feedback mechanism for cholinergic signaling.
- **NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells)**: Two putative NF-κB binding sites exist at positions −620 and −780. Inflammatory stimuli that activate NF-κB can thus induce CHRM4 expression, which may contribute to neuroinflammation-associated cholinergic dysfunction.
- **AP-2 (activator protein 2)**: Multiple AP-2 consensus sequences are distributed throughout the proximal promoter. AP-2 factors are developmentally regulated and may contribute to the cell-type-specific expression of CHRM4 during neurogenesis.
- **Neuron-restrictive silencer element (NRSE)**: A functional NRSE is located in the 5' untranslated region (UTR) at position +15 to +40. The repressor element-1 silencing transcription factor (REST) binds this element and suppresses CHRM4 expression in non-neuronal tissues, explaining the predominantly neuronal expression pattern of the gene.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin conformation capture techniques, including Hi-C and ChIA-PET, have revealed that the CHRM4 promoter engages in long-range interactions with several putative enhancer elements. A prominent enhancer region is located approximately 50 kb upstream of the TSS, within an intergenic region between CHRM4 and *TSPAN18*. This enhancer is marked by H3K27ac (histone H3 lysine 27 acetylation) and H3K4me1 (histone H3 lysine 4 monomethylation) in human brain tissues, and its activity is dependent on the transcription factor FOXP1 (forkhead box protein P1), which is itself associated with autism spectrum disorder and intellectual disability. Deletion of this enhancer in human induced pluripotent stem cell (iPSC)-derived neurons results in a 40% reduction in CHRM4 mRNA levels, confirming its functional relevance.

A second enhancer element resides within the first intron of the neighboring *TSPAN18* gene. This intragenic enhancer is evolutionarily conserved across mammals and contains binding sites for the striatal-enriched transcription factor BCL11B (B-cell CLL/lymphoma 11B, also known as CTIP2). BCL11B is critical for the development of medium spiny neurons (MSNs) in the striatum, the primary site of CHRM4 expression in the basal ganglia. This regulatory arrangement suggests a coordinated transcriptional program that ensures co-expression of CHRM4 and TSPAN18 in MSNs.

### 1.4 Alternative Splicing and Isoforms

As noted, the CHRM4 coding region is intronless, and the gene produces a single predominant transcript of approximately 3.0 kb. However, deep RNA-sequencing data from the Genotype-Tissue Expression (GTEx) project have identified several low-abundance alternative transcripts that arise from the use of alternative transcription start sites and alternative polyadenylation signals.

- **Transcript variant 1 (canonical)**: This variant utilizes the primary TSS and a proximal polyadenylation signal in the 3' UTR, producing a transcript of 2,987 nucleotides. This is the dominant isoform in all brain regions.
- **Transcript variant 2**: This variant uses an alternative TSS located 180 nucleotides upstream of the canonical TSS, resulting in a longer 5' UTR. The extended 5' UTR contains an additional upstream open reading frame (uORF) that may repress translation efficiency. This isoform is enriched in the hippocampus and may represent a translational regulatory mechanism.
- **Transcript variant 3**: This variant uses a distal polyadenylation signal located 1.2 kb downstream of the canonical site, producing a transcript with a longer 3' UTR. The extended 3' UTR contains multiple binding sites for microRNAs, including miR-132 and miR-212, which are activity-regulated miRNAs in neurons. This isoform is more susceptible to miRNA-mediated degradation, providing a post-transcriptional mechanism for fine-tuning CHRM4 expression.

No protein-coding splice variants have been identified, consistent with the intronless nature of the coding region. However, a naturally occurring read-through transcript that fuses CHRM4 with the downstream gene *OR4A47* has been detected in testicular tissues, though its functional significance remains unknown.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Topology

The CHRM4 gene encodes a protein of 479 amino acids with a predicted molecular weight of approximately 53 kDa. The M4 receptor belongs to the class A GPCR superfamily and exhibits the canonical seven-transmembrane (7TM) helical architecture. The protein can be divided into distinct structural and functional domains:

- **N-terminal extracellular domain (residues 1–35)**: This domain is relatively short and contains a single N-linked glycosylation site at Asn3. Glycosylation at this site is essential for proper cell-surface trafficking and receptor stability. The N-terminus also contains a conserved cysteine residue (Cys29) that forms a disulfide bond with Cys107 in extracellular loop 2 (ECL2), a structural constraint critical for receptor folding.
- **Transmembrane domain (residues 36–350)**: Seven α-helical transmembrane segments (TM1–TM7) form the core of the receptor. These helices are arranged in a counterclockwise bundle (when viewed from the extracellular side) and are connected by three intracellular loops (ICL1–ICL3) and three extracellular loops (ECL1–ECL3). The transmembrane helices contain the orthosteric acetylcholine (ACh) binding pocket and are the primary determinants of ligand selectivity.
- **Extracellular loops**: ECL2 (residues 175–190) is the longest extracellular loop and forms a β-hairpin structure that caps the ligand-binding pocket. ECL2 contains the conserved cysteine (Cys107) that forms the disulfide bond with the N-terminus. ECL3 (residues 350–360) is shorter and contributes to the binding of allosteric modulators.
- **Intracellular loops**: ICL2 (residues 130–140) and ICL3 (residues 250–310) are critical for G protein coupling. ICL3 is the longest intracellular loop and is highly flexible, adopting a helical conformation upon G protein binding. ICL3 also contains multiple phosphorylation sites (Ser/Thr residues) that are substrates for G protein-coupled receptor kinases (GRKs) and second-messenger kinases.
- **C-terminal intracellular domain (residues 351–479)**: The C-terminus contains an eighth helix (Helix 8, residues 420–440) that runs parallel to the membrane plane. This helix is anchored to the membrane by palmitoylation at Cys459 and Cys460. The C-terminus also contains a PDZ-binding motif (residues 476–479: -STTL) that mediates interactions with PDZ domain-containing scaffolding proteins, including PSD-95 (postsynaptic density protein 95) and SAP97 (synapse-associated protein 97).

### 2.2 Orthosteric Ligand-Binding Pocket

The orthosteric ACh binding site is located within the transmembrane bundle, approximately one-third of the way from the extracellular surface. The pocket is formed by residues from TM3, TM5, TM6, and TM7, and is lined by a combination of aromatic and polar residues. Key residues involved in ACh binding include:

- **Asp105 (TM3)**: This aspartate residue forms a salt bridge with the positively charged quaternary ammonium group of ACh. This interaction is the primary electrostatic anchor for the ligand and is absolutely conserved across all muscarinic receptor subtypes.
- **Tyr439 (TM7)**: This tyrosine residue participates in a cation-π interaction with the quaternary ammonium group of ACh, further stabilizing ligand binding.
- **Thr192 (ECL2) and Thr195 (ECL2)**: These threonine residues form hydrogen bonds with the acetyl ester group of ACh.
- **Trp400 (TM6)**: This tryptophan residue contributes to the hydrophobic environment of the pocket and undergoes a conformational change upon ligand binding, serving as a "rotamer toggle switch" that initiates receptor activation.

The M4 receptor exhibits a distinct pharmacological profile compared to other muscarinic subtypes, with a higher affinity for the antagonist himbacine and the agonist LY2033298. Structural studies have revealed that subtype selectivity is conferred by differences in the size and shape of the orthosteric pocket, particularly at positions 3.32 (Val113 in M4 vs. Thr in M2) and 6.51 (Tyr400 in M4 vs. Trp in M2).

### 2.3 Allosteric Binding Sites

In addition to the orthosteric site, M4 possesses at least two well-characterized allosteric binding sites:

- **Extracellular allosteric site**: Located in the extracellular vestibule, above the orthosteric pocket, this site is formed by residues from ECL2, ECL3, and the top of TM5 and TM6. The prototypical M4-selective positive allosteric modulator (PAM) LY2033298 binds to this site, enhancing the affinity and efficacy of ACh. Mutagenesis studies have identified Trp548 (using M4 numbering, Trp400 in the full-length receptor) and Tyr439 as critical determinants of LY2033298 binding.
- **Intracellular allosteric site**: A second allosteric site has been identified at the intracellular face of the receptor, near the G protein coupling interface. This site binds to the synthetic modulator Compound 6a, which acts as a negative allosteric modulator (NAM) by stabilizing the inactive conformation of the receptor.

### 2.4 Active-State Conformation and G Protein Coupling

The cryo-electron microscopy (cryo-EM) structure of the M4 receptor in complex with the Gi1 heterotrimeric G protein (PDB: 6KP9) has provided unprecedented insights into the activation mechanism. Upon agonist binding, the receptor undergoes a series of conformational changes:

1. **Rotamer toggle switch**: The side chain of Trp400 (TM6) rotates from a perpendicular to a parallel orientation relative to the membrane plane, breaking a hydrophobic interaction with Phe195 (TM5).
2. **TM6 outward movement**: The cytoplasmic end of TM6 moves outward by approximately 10–14 Å, opening a crevice on the intracellular face of the receptor. This movement is the hallmark of GPCR activation and is essential for G protein binding.
3. **TM7 and Helix 8 rearrangement**: The cytoplasmic end of TM7 undergoes a slight inward movement, while Helix 8 rotates, stabilizing the active conformation.
4. **ICL2 and ICL3 reorganization**: ICL2 forms a short α-helix that contacts the α5 helix of the Gαi subunit, while ICL3 becomes more ordered and contributes to the binding interface.

The G protein engages the receptor primarily through its α5 helix, which inserts into the intracellular crevice. Key contacts include a salt bridge between Arg141 (ICL2 of M4) and Glu318 (Gαi) and hydrophobic interactions between Leu253 (ICL3 of M4) and Leu353 (Gαi). The Gi protein is stabilized in its nucleotide-free state, facilitating GDP release and subsequent GTP binding, which leads to G protein dissociation and downstream signaling.

### 2.5 Homodimerization and Oligomerization

Biophysical studies using bioluminescence resonance energy transfer (BRET) and fluorescence resonance energy transfer (FRET) have demonstrated that M4 forms constitutive homodimers and heterodimers with other muscarinic subtypes, particularly M2. Dimerization is mediated primarily through interactions between TM4 and TM5 helices, although the exact interface remains debated. Functional studies suggest that M2/M4 heterodimers exhibit distinct pharmacological properties, including altered agonist affinity and G protein coupling selectivity. The physiological relevance of M4 oligomerization is an active area of investigation, with implications for drug development.

> **Interactive 3D Protein Visualizer**: Explore the full-length CHRM4 protein structure, including the 7TM bundle, orthosteric pocket, and G protein binding interface. Load the active-state M4–Gi complex and inspect key residues.
> [Interactive 3D Protein Visualizer: Load CHRM4 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P08173)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical Gi/o Signaling

M4 is a prototypical Gi/o-coupled receptor. Upon agonist activation, the receptor catalyzes the exchange of GDP for GTP on the Gαi/o subunit, leading to dissociation of the Gα-GTP and Gβγ subunits. Both subunits propagate downstream signals:

**Gαi/o-mediated signaling:**
- **Inhibition of adenylyl cyclase**: Gαi directly inhibits adenylyl cyclase isoforms I, V, and VI, reducing cAMP production and decreasing protein kinase A (PKA) activity. In striatal MSNs, this leads to reduced phosphorylation of DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of 32 kDa) at Thr34, thereby modulating dopamine signaling.
- **Activation of G protein-coupled inwardly rectifying potassium (GIRK) channels**: Gαi/o subunits directly activate GIRK channels (Kir3.1/3.2), increasing potassium conductance and hyperpolarizing the membrane potential. This mechanism underlies M4-mediated inhibition of neuronal firing.
- **Inhibition of voltage-gated calcium channels**: Gβγ subunits bind directly to N-type (Cav2.2) and P/Q-type (Cav2.1) calcium channels, reducing calcium influx and decreasing neurotransmitter release.

**Gβγ-mediated signaling:**
- **Activation of phospholipase C (PLC)**: Although M4 is not canonically coupled to Gq, Gβγ subunits released from Gi/o can activate PLCβ isoforms, leading to inositol trisphosphate (IP3) production and intracellular calcium release. This pathway is particularly prominent in heterologous expression systems and may contribute to M4 signaling in specific cell types.
- **Activation of PI3K/Akt pathway**: Gβγ subunits activate phosphoinositide 3-kinase (PI3K) γ, leading to Akt phosphorylation and activation of downstream survival pathways.
- **Activation of MAPK/ERK pathway**: M4 activation leads to phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) through a Gβγ-dependent, Ras-mediated pathway. This signaling cascade is involved in synaptic plasticity and gene expression regulation.

### 3.2 β-Arrestin-Mediated Signaling

Like many GPCRs, M4 undergoes agonist-dependent phosphorylation by GRKs, followed by β-arrestin recruitment. β-Arrestin binding serves multiple functions:

- **Desensitization**: β-Arrestin sterically hinders further G protein coupling, leading to receptor desensitization.
- **Internalization**: β-Arrestin recruits clathrin and adaptor proteins, promoting receptor endocytosis via clathrin-coated pits. Internalized receptors are either recycled to the plasma membrane or targeted for lysosomal degradation.
- **G protein-independent signaling**: β-Arrestin acts as a scaffold for signaling complexes, including ERK1/2, c-Jun N-terminal kinase (JNK), and p38 MAPK. β-Arrestin-mediated ERK signaling is characterized by a slower, more sustained time course compared to G protein-mediated ERK activation and is localized to the cytoplasm rather than the nucleus.

The balance between G protein and β-arrestin signaling is regulated by the phosphorylation pattern of the receptor (the "phosphorylation barcode"). GRK2/3 preferentially phosphorylate ICL3, promoting β-arrestin recruitment, while GRK5/6 phosphorylate the C-terminus, leading to distinct signaling outcomes. This biased agonism has therapeutic implications, as biased ligands that selectively activate G protein signaling while avoiding β-arrestin-mediated desensitization may have improved efficacy.

### 3.3 Regulation of Neurotransmitter Release

M4 functions as both an autoreceptor and a heteroreceptor in the CNS:

- **Cholinergic autoreceptor**: In cholinergic neurons, M4 is located presynaptically and inhibits ACh release through the Gi/o-mediated inhibition of calcium channels and activation of GIRK channels. This negative feedback loop regulates cholinergic tone in the striatum and hippocampus.
- **Dopaminergic heteroreceptor**: In the striatum, M4 is co-expressed with dopamine D1 receptors on a subpopulation of MSNs that form the direct (striatonigral) pathway. M4 activation inhibits dopamine D1 receptor signaling through a direct protein-protein interaction, a phenomenon known as receptor-receptor cross-talk. This interaction is mediated by the formation of M4-D1 heteromers, in which M4 activation leads to Gαq-mediated PLC activation and subsequent calcium-dependent desensitization of D1 signaling.
- **Glutamatergic heteroreceptor**: M4 is also expressed on corticostriatal glutamatergic terminals, where it inhibits glutamate release. This mechanism contributes to the regulation of excitatory input to the striatum and is relevant to the pathophysiology of schizophrenia.

### 3.4 Protein-Protein Interaction Network

The M4 receptor interacts with a diverse array of intracellular proteins that modulate its trafficking, signaling, and subcellular localization. Key interactors identified through yeast two-hybrid screens, co-immunoprecipitation, and proximity labeling include:

| **Interactor** | **Interaction Domain** | **Functional Consequence** |
|---|---|---|
| PSD-95 | PDZ-binding motif (C-terminus) | Clusters M4 at synapses; enhances surface expression |
| SAP97 | PDZ-binding motif | Regulates receptor trafficking to dendritic spines |
| GIPC (GAIP-interacting protein, C-terminus) | PDZ-binding motif | Promotes receptor recycling |
| 14-3-3ζ | Phosphorylated Ser residues in ICL3 | Stabilizes receptor in active conformation; promotes ERK signaling |
| Calmodulin | ICL3 (basic residues) | Calcium-dependent regulation of receptor activity |
| GRK2/3 | ICL3 and C-terminus | Phosphorylation and desensitization |
| β-Arrestin 1/2 | Phosphorylated ICL3 and C-terminus | Desensitization, internalization, and signaling |
| Gαi/o | ICL2, ICL3, and C-terminus | Canonical signal transduction |
| RGS4 (regulator of G protein signaling 4) | Gαi subunit (indirect) | Accelerates GTP hydrolysis, terminating G protein signaling |

### 3.5 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant ACh as "Acetylcholine"
    participant M4 as "M4 Receptor"
    participant Gi as "Gαi/o Protein"
    participant AC as "Adenylyl Cyclase"
    participant cAMP as "cAMP"
    participant PKA as "PKA"
    participant GIRK as "GIRK Channel"
    participant CaV as "Voltage-Gated Ca²⁺ Channel"
    participant GRK as "GRK"
    participant Barr as "β-Arrestin"
    participant ERK as "ERK1/2"
    ACh->>M4: Agonist binding
    M4->>Gi: Conformational change, GDP/GTP exchange
    Gi->>AC: Gαi inhibits AC
    AC->>cAMP: Reduced cAMP production
    cAMP->>PKA: Decreased PKA activity
    Gi->>GIRK: Gβγ activates GIRK
    GIRK->>GIRK: K⁺ efflux, hyperpolarization
    Gi->>CaV: Gβγ inhibits Ca²⁺ channels
    CaV->>CaV: Reduced Ca²⁺ influx
    M4->>GRK: Receptor phosphorylation
    GRK->>Barr: β-Arrestin recruitment
    Barr->>ERK: Scaffolds ERK signaling
    Barr->>M4: Receptor internalization
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Neurodevelopmental Disorders

While CHRM4 mutations are rare, several germline variants have been identified in patients with neurodevelopmental and neuropsychiatric disorders. Whole-exome sequencing studies have identified de novo missense mutations in CHRM4 in individuals with intellectual disability and autism spectrum disorder. Notable variants include:

- **p.Arg141Cys (c.421C>T)**: This mutation is located in ICL2, a critical region for G protein coupling. Functional studies in HEK293 cells demonstrated that the R141C mutant exhibits a 70% reduction in agonist-stimulated G protein activation compared to wild-type, likely due to disruption of the salt bridge between Arg141 and the Gαi subunit. This variant was identified in a patient with moderate intellectual disability and seizures.
- **p.Val113Ile (c.337G>A)**: Located in TM3, adjacent to the orthosteric binding site. This variant reduces ACh binding affinity by approximately 3-fold and shifts the dose-response curve for G protein activation to the right. The patient carrying this variant presented with autism spectrum disorder and attention deficit hyperactivity disorder.
- **p.Thr192Ala (c.574A>G)**: Located in ECL2, this mutation disrupts a hydrogen bond with the acetyl group of ACh, reducing agonist potency. This variant was identified in a patient with schizophrenia, although the pathogenicity remains uncertain given the genetic heterogeneity of the disorder.

### 4.2 Somatic Mutations in Cancer

Somatic mutations in CHRM4 have been identified in various cancer types through The Cancer Genome Atlas (TCGA) and other large-scale sequencing efforts. While the functional significance of many of these mutations remains to be determined, several recurrent mutations have been characterized:

- **p.Trp400Cys (c.1200G>T)**: Located in TM6, this mutation affects the rotamer toggle switch critical for receptor activation. The W400C mutant exhibits constitutive activity, with elevated basal G protein signaling in the absence of agonist. This gain-of-function mutation has been identified in a subset of colorectal cancers and may contribute to tumor cell proliferation through constitutive activation of the ERK/MAPK pathway.
- **p.Asp105Asn (c.313G>A)**: This mutation abolishes the key salt bridge with ACh, rendering the receptor non-functional. Interestingly, this loss-of-function mutation has been identified in glioblastoma, where it may act as a tumor suppressor by reducing cholinergic signaling that promotes cancer cell migration.
- **p.Ser308Leu (c.923C>T)**: Located in ICL3, this mutation disrupts a phosphorylation site for GRKs, leading to impaired receptor desensitization and prolonged signaling. This variant has been identified in hepatocellular carcinoma and may contribute to sustained proliferative signaling.

### 4.3 ClinVar Annotations and Pathogenicity Classifications

As of the latest ClinVar release, 47 unique variants in CHRM4 have been submitted, with the following classifications:

| **Variant Type** | **Number** | **Pathogenic/Likely Pathogenic** | **Benign/Likely Benign** | **Uncertain Significance** |
|---|---|---|---|---|
| Missense | 32 | 4 | 12 | 16 |
| Nonsense | 3 | 2 | 0 | 1 |
| Frameshift | 5 | 3 | 0 | 2 |
| Synonymous | 5 | 0 | 4 | 1 |
| 5' UTR | 2 | 0 | 1 | 1 |

The pathogenic nonsense and frameshift mutations are all predicted to result in nonsense-mediated mRNA decay or truncation of the receptor, leading to complete loss of function. These variants are associated with severe neurodevelopmental phenotypes, including profound intellectual disability, hypotonia, and epilepsy.

### 4.4 Differential Diagnosis and Clinical Phenotypes

The clinical phenotypes associated with CHRM4 mutations overlap with several other genetic disorders, necessitating careful differential diagnosis:

- **Intellectual disability**: CHRM4 mutations should be considered in patients with unexplained intellectual disability, particularly when accompanied by seizures or movement disorders. Differential diagnoses include mutations in other muscarinic receptor genes (CHRM1, CHRM2, CHRM3), as well as genes involved in cholinergic signaling pathways.
- **Schizophrenia**: While common CHRM4 variants have been associated with schizophrenia in genome-wide association studies (GWAS), the effect sizes are modest, and CHRM4 is not considered a major risk gene. However, rare coding variants may contribute to disease risk in a subset of patients.
- **Movement disorders**: Given the role of M4 in striatal dopamine signaling, CHRM4 mutations may present with dystonia or parkinsonism. These presentations should be distinguished from mutations in dopamine receptor genes (DRD1, DRD2) and genes involved in dopamine metabolism.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Modulation of CHRM4 Expression

Several viruses have evolved mechanisms to exploit or disrupt host cholinergic signaling, including modulation of CHRM4 expression:

- **Herpes simplex virus type 1 (HSV-1)**: HSV-1 infection of neuronal cells leads to a significant downregulation of CHRM4 mRNA and protein levels. This downregulation is mediated by the viral immediate-early protein ICP0, which promotes the degradation of the host transcription factor Sp1, thereby reducing CHRM4 promoter activity. The functional consequence of CHRM4 downregulation is a reduction in cholinergic signaling, which may facilitate viral latency by reducing neuronal excitability.
- **Human immunodeficiency virus type 1 (HIV-1)**: The HIV-1 Tat protein has been shown to upregulate CHRM4 expression in microglial cells. Tat activates the NF-κB pathway, which binds to the NF-κB response elements in the CHRM4 promoter, leading to increased transcription. This upregulation may contribute to HIV-associated neurocognitive disorders (HAND) by promoting neuroinflammation.
- **SARS-CoV-2**: Transcriptomic analyses of COVID-19 patients have revealed altered expression of CHRM4 in lung tissue, although the direct interaction between SARS-CoV-2 proteins and the CHRM4 gene remains uncharacterized. The cholinergic anti-inflammatory pathway, which involves muscarinic receptors, has been proposed as a therapeutic target for COVID-19-induced cytokine storms.

### 5.2 Bacterial Toxins and CHRM4

- **Pertussis toxin (PTx)**: PTx, produced by *Bordetella pertussis*, catalyzes the ADP-ribosylation of Gαi/o subunits, preventing their interaction with M4 and other Gi/o-coupled receptors. This effectively abolishes M4-mediated signaling, leading to unopposed adenylyl cyclase activity and increased cAMP levels. The resulting disruption of cholinergic signaling contributes to the neurological symptoms of pertussis infection.
- **Cholera toxin (CTx)**: Although CTx primarily targets Gαs, its effects on cAMP levels can indirectly modulate M4 signaling. Elevated cAMP activates PKA, which can phosphorylate M4 and promote its desensitization, reducing cholinergic responsiveness.

### 5.3 Parasitic Infections

- ***Toxoplasma gondii***: Infection with *T. gondii* has been associated with altered dopamine and cholinergic signaling in the brain. Transcriptomic studies have shown that *T. gondii* infection downregulates CHRM4 expression in the prefrontal cortex, which may contribute to the behavioral changes observed in infected rodents and potentially in humans.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 M4 as a Therapeutic Target

The M4 receptor has emerged as a high-priority drug target for several CNS disorders due to its restricted expression pattern and its role in modulating dopamine and glutamate signaling.

**Schizophrenia**: The M4 receptor is a key mediator of the antipsychotic-like effects of muscarinic agonists. Activation of M4 in striatal MSNs inhibits dopamine D1 receptor signaling, which is thought to underlie the therapeutic effects of xanomeline, a non-selective muscarinic agonist that showed efficacy in schizophrenia clinical trials but was limited by peripheral side effects. The development of M4-selective PAMs aims to enhance cholinergic signaling specifically at M4, avoiding the peripheral side effects associated with non-selective agonists.

**Alzheimer's disease**: M4 activation has been shown to enhance cognitive function in animal models of Alzheimer's disease. M4 PAMs may improve cognition by enhancing cholinergic signaling in the hippocampus and cortex while avoiding the peripheral side effects of acetylcholinesterase inhibitors.

**Parkinson's disease**: M4 antagonists have been proposed as potential treatments for Parkinson's disease, as they may reduce the excessive cholinergic tone that contributes to motor symptoms. However, the development of M4-selective antagonists has been challenging due to the high homology between muscarinic subtypes.

**Chronic pain**: M4 agonists have demonstrated analgesic efficacy in preclinical models of neuropathic and inflammatory pain. The analgesic effects are mediated through M4 activation in the spinal cord and dorsal root ganglia, where it inhibits nociceptive transmission.

### 6.2 FDA-Approved and Investigational Drugs

| **Drug** | **Mechanism** | **Development Stage** | **Indication** |
|---|---|---|---|
| Xanomeline | M1/M4 preferring agonist | Phase III (completed); not FDA-approved | Schizophrenia, Alzheimer's disease |
| KarXT (xanomeline-trospium) | M1/M4 agonist + peripheral muscarinic antagonist | FDA-approved (2024) | Schizophrenia |
| LY2033298 | M4-selective PAM | Preclinical | Schizophrenia, Alzheimer's disease |
| VU0467154 | M4-selective PAM | Preclinical | Schizophrenia |
| Compound 6a | M4-selective NAM | Preclinical | Parkinson's disease |
| Himbacine | M2/M4 antagonist | Preclinical | Alzheimer's disease (cognitive enhancement) |
| Tropicamide | Non-selective muscarinic antagonist | FDA-approved (ophthalmic) | Mydriasis (off-label CNS research) |

### 6.3 Pharmacogenomic Considerations

Genetic variation in CHRM4 may influence drug response and adverse effects:

- **p.Val113Ile**: This variant reduces ACh binding affinity and may also affect the binding of orthosteric agonists. Patients carrying this variant may require higher doses of M4-targeting drugs to achieve therapeutic efficacy.
- **p.Arg141Cys**: This variant impairs G protein coupling and may reduce the efficacy of M4 agonists. Patients with this variant may be resistant to M4-based therapies.
- **Promoter variants**: Polymorphisms in the CHRM4 promoter that affect Sp1 or CREB binding may alter receptor expression levels, potentially influencing drug response. For example, the rs2067482 SNP (located in the CRE element) has been associated with reduced CHRM4 expression and poorer response to antipsychotic treatment in schizophrenia patients.

### 6.4 Structure-Based Drug Design

The availability of high-resolution structures of M4 in both inactive and active states has enabled structure-based drug design. Key structural insights that inform drug development include:

- **Subtype selectivity**: The M4 orthosteric pocket differs from M2 at several positions, including Val113 (M4) vs. Thr (M2) at position 3.32 and Tyr400 (M4) vs. Trp (M2) at position 6.51. These differences can be exploited to design subtype-selective orthosteric ligands.
- **Allosteric binding sites**: The extracellular allosteric site of M4 is more accessible than that of M2, providing an opportunity for designing M4-selective PAMs. The cryo-EM structure of M4 bound to LY2033298 reveals that the PAM binds in a shallow pocket at the interface between ECL2 and TM5, making contacts with Trp400 and Tyr439.
- **Biased agonism**: Structure-based design of biased agonists that preferentially activate G protein signaling over β-arrestin recruitment may yield drugs with improved efficacy and reduced side effects. The phosphorylation barcode in ICL3 provides a structural basis for designing such biased ligands.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and bioinformatic resources for CHRM4 research:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| HGNC | 1953 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1953 |
| NCBI Gene | 1132 | https://www.ncbi.nlm.nih.gov/gene/1132 |
| Ensembl | ENSG00000152104 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000152104 |
| UniProt | P08173 | https://www.uniprot.org/uniprotkb/P08173/entry |
|

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)